GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Bionik Laboratories Corp (OTCPK:BNKL) » Definitions » Beneish M-Score
中文

Bionik Laboratories (Bionik Laboratories) Beneish M-Score : 0.00 (As of Apr. 25, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Bionik Laboratories Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Bionik Laboratories's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Bionik Laboratories was 0.00. The lowest was 0.00. And the median was 0.00.


Bionik Laboratories Beneish M-Score Historical Data

The historical data trend for Bionik Laboratories's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionik Laboratories Beneish M-Score Chart

Bionik Laboratories Annual Data
Trend Dec14 Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 -4.24 -4.59 -4.44 -

Bionik Laboratories Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.44 -5.35 5.79 - -

Competitive Comparison of Bionik Laboratories's Beneish M-Score

For the Medical Care Facilities subindustry, Bionik Laboratories's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bionik Laboratories's Beneish M-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Bionik Laboratories's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bionik Laboratories's Beneish M-Score falls into.



Bionik Laboratories Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bionik Laboratories for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Total Receivables was $0.45 Mil.
Revenue was 0.501 + 0.575 + 0.486 + 0.243 = $1.81 Mil.
Gross Profit was 0.254 + 0.271 + 0.298 + 0.168 = $0.99 Mil.
Total Current Assets was $2.78 Mil.
Total Assets was $3.36 Mil.
Property, Plant and Equipment(Net PPE) was $0.44 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.06 Mil.
Selling, General, & Admin. Expense(SGA) was $4.91 Mil.
Total Current Liabilities was $2.31 Mil.
Long-Term Debt & Capital Lease Obligation was $2.39 Mil.
Net Income was -1.356 + -1.076 + -1.129 + -1.384 = $-4.95 Mil.
Non Operating Income was -0.005 + -0.002 + -0.001 + -0.006 = $-0.01 Mil.
Cash Flow from Operations was -0.757 + -0.513 + -0.955 + -1.162 = $-3.39 Mil.
Total Receivables was $0.28 Mil.
Revenue was 0.191 + 0.183 + 0.228 + 0.671 = $1.27 Mil.
Gross Profit was 0.133 + 0.133 + 0.147 + 0.541 = $0.95 Mil.
Total Current Assets was $4.59 Mil.
Total Assets was $4.68 Mil.
Property, Plant and Equipment(Net PPE) was $0.09 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.10 Mil.
Selling, General, & Admin. Expense(SGA) was $4.73 Mil.
Total Current Liabilities was $1.49 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.453 / 1.805) / (0.275 / 1.273)
=0.25097 / 0.216025
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.954 / 1.273) / (0.991 / 1.805)
=0.749411 / 0.54903
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2.778 + 0.442) / 3.362) / (1 - (4.585 + 0.091) / 4.676)
=0.042237 / 0
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.805 / 1.273
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.103 / (0.103 + 0.091)) / (0.063 / (0.063 + 0.442))
=0.530928 / 0.124752
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(4.912 / 1.805) / (4.728 / 1.273)
=2.72133 / 3.714061
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.39 + 2.309) / 3.362) / ((0 + 1.492) / 4.676)
=1.39768 / 0.319076
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-4.945 - -0.014 - -3.387) / 3.362
=-0.45925

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


Bionik Laboratories Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Bionik Laboratories's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionik Laboratories (Bionik Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
80 Coolidge Hill Road, Watertown, MA, USA, 02472
Bionik Laboratories Corp is a healthcare company focused on improving the quality of life of millions of people with neurological or mobility impairments by combining artificial intelligence and innovative robotics technology to help individuals from hospital to home regain mobility, enhance autonomy, and regain self-esteem. The company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver a greater recovery for patients with neurological or mobility impairments. Its products The InMotion ARM, and InMotion ARM/HAND are robotic therapies for the upper limbs.
Executives
Remi Gaston-dreyfus director, 10 percent owner 46 RUE PIERRE CHARRON, PARIS I0 75008
Charles Matine director 7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017
Andre-jacques Auberton-herve director, officer: Chairman 18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700
Daniel Gonsalves officer: Executive Vice President & CFO 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Loren W. Wass officer: See Remarks 34 HOG HILL ROAD, PEPPERELL MA 01463
Joseph R Martin director
Audrey Thevenon director 4500 WESTBROOK LANE, KENSINGTON MD 20895
Peter Gerald Malone director
Russo Richard Paul Jr officer: Chief Financial Officer 20 PLUNKETT WAY, TEWKSBURY MA 01876
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
Timothy A. Mccarthy officer: Chief Commercialization Office C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9
Eric Michel Dusseux director 1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300
Jules Marc Fried officer: VP - U.S. Operations C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Hermano Igo Krebs officer: Chief Science Officer C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472
Marc Mathieu director 716 BROOKS AVENUE, VENICE CA 90291